Following the arrival of the coronavirus in the U.S., people with cancer and their doctors are adjusting to new ways of doing things while continuing to seek and provide cancer care.
by Kate Yandell
COVID-19 slowed or stopped enrollment in some cancer clinical trials.
Data shed light on risk factors for death among people with cancer infected with the coronavirus.
Researchers from around the globe share insights into the outcomes of people with cancer who are infected with the coronavirus.
by Bradley Jones
At the AACR Virtual Annual Meeting I, researchers presented data on blood tests that aim to supplement current cancer screening and speed up diagnosis.
For a small group of pancreatic cancer patients who were able to receive therapies targeting the molecular alterations in their tumors, these matched therapies were associated with longer life.
by Cheryl Platzman Weinstock
People being treated for cancer may be at elevated risk of developing severe cases of COVID-19. The coronavirus is also affecting how cancer care is delivered.
by William G. Nelson, MD, PhD
Cancer centers are taking advantage of their in-house molecular laboratories to selectively test certain cancer patients for the coronavirus.
by Anna Azvolinsky
From The Editor-In-Chief
Emerging insights into epigenetic abnormalities in cancer cells may lead to better cancer outcomes.
FORWARD LOOK
Procedure uses extreme cold to kill cancer cells.
by Christina Bennett
I have brain cancer, and my wife is a health care worker. These are some questions we had to consider leading up to and after her diagnosis with COVID-19.
by Adam Hayden
Identifying patients whose cancers will have durable responses to checkpoint inhibitors can guide treatment.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with metastatic prostate cancer.
Bladder cancer is the sixth most prevalent cancer in the United States and has a high rate of recurrence.
Handle With Care
donate to the AACR